Sichuan Hebang Biotechnology Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Sichuan Hebang Biotechnology has a total shareholder equity of CN¥19.4B and total debt of CN¥3.4B, which brings its debt-to-equity ratio to 17.6%. Its total assets and total liabilities are CN¥26.0B and CN¥6.6B respectively. Sichuan Hebang Biotechnology's EBIT is CN¥572.4M making its interest coverage ratio -9. It has cash and short-term investments of CN¥2.6B.
Anahtar bilgiler
17.6%
Borç/özkaynak oranı
CN¥3.41b
Borç
| Faiz karşılama oranı | -9x |
| Nakit | CN¥2.57b |
| Eşitlik | CN¥19.38b |
| Toplam yükümlülükler | CN¥6.59b |
| Toplam varlıklar | CN¥25.98b |
Son finansal sağlık güncellemeleri
Recent updates
Returns On Capital At Sichuan Hebang Biotechnology (SHSE:603077) Have Stalled
Sep 25
Sichuan Hebang Biotechnology Corporation Limited's (SHSE:603077) Shares Not Telling The Full Story
Aug 16Return Trends At Sichuan Hebang Biotechnology (SHSE:603077) Aren't Appealing
Jun 04Investors Holding Back On Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077)
May 13Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?
Mar 07Here's Why I Think Sichuan Hebang Biotechnology (SHSE:603077) Is An Interesting Stock
Apr 21Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 603077's short term assets (CN¥10.8B) exceed its short term liabilities (CN¥5.8B).
Uzun Vadeli Yükümlülükler: 603077's short term assets (CN¥10.8B) exceed its long term liabilities (CN¥832.3M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 603077's net debt to equity ratio (4.4%) is considered satisfactory.
Borcun Azaltılması: 603077's debt to equity ratio has increased from 15.7% to 17.6% over the past 5 years.
Borç Kapsamı: 603077's operating cash flow is negative, therefore debt is not well covered.
Faiz Kapsamı: 603077 earns more interest than it pays, so coverage of interest payments is not a concern.